Compare DSL & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DSL | AAPG |
|---|---|---|
| Founded | 2013 | 2009 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 2013 | 2024 |
| Metric | DSL | AAPG |
|---|---|---|
| Price | $9.83 | $14.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $47.13 |
| AVG Volume (30 Days) | ★ 723.3K | 4.4K |
| Earning Date | 01-01-0001 | 08-19-2026 |
| Dividend Yield | ★ 13.44% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $21.37 |
| Revenue Next Year | N/A | $112.93 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.82 | $14.55 |
| 52 Week High | $12.34 | $40.23 |
| Indicator | DSL | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 29.03 | 47.18 |
| Support Level | N/A | $14.55 |
| Resistance Level | $11.04 | $16.18 |
| Average True Range (ATR) | 0.12 | 0.39 |
| MACD | -0.01 | 0.06 |
| Stochastic Oscillator | 9.55 | 59.08 |
DoubleLine Income Solutions Fund is a closed-end management investment company. Its primary investment objective is to seek high income and its secondary objective is to seek capital appreciation. It invests in debt securities and other income-producing investments anywhere in the world, including emerging markets. The company's investment portfolio comprises foreign corporate bonds, U.S. corporate bonds, bank loans, collateralized loan obligations, non-agency commercial mortgage backed obligations, asset-backed obligations, and municipal bonds among others.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.